Cisplatin and 4-hexylresorcinol synergise to decrease metastasis and increase survival rate in an oral mucosal melanoma xenograft model: A preliminary study

Tumor Biology

Volumn 34, Issue 3, 2013, Pages 1595-1603

  Lee, Sang Woon ^a   Kim, Seong Gon ^a   Park, Young Wook ^a   Kweon, Haeyong ^b   Kim, Jwa Young ^c   Rotaru, Horatiu ^d  

^a Gangneung Wonju National University   (South Korea)

^b National Institute of Animal Science   (South Korea)

^c Hallym University   (South Korea)

^d IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

4 hexylresorcinol; Cisplatin; Matrix metalloproteinases 2; Oral mucosal melanoma

Indexed keywords

CISPLATIN; DACARBAZINE; GELATINASE A; HEXYLRESORCINOL; IMATINIB; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISTANT METASTASIS; DNA MICROARRAY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; GELATINASE A GENE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; MALE; METASTASIS; MICRO-COMPUTED TOMOGRAPHY; MITOSIS INHIBITION; MOUSE; MOUTH CANCER; NONHUMAN; NUCLEOTIDE SEQUENCE; ORAL MUCOSA MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84878745218     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0690-6     Document Type: Article

References (45)

1. Rapini RP, Golitz LE, Greer RO, et al. Primary malignant melanoma of the oral cavity. A review of 177 cases. Cancer. 1985;55:1543-51.
2. Hicks MJ, Flaitz CM. Oral mucosal melanoma: epidemiology and pathobiology. Oral Oncol. 2000;36:152-69.
3. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1664-78.
4. Tanaka N, Mimura M, Ogi K, et al. Primary malignant melanoma of the oral cavity: assessment of outcome from the clinical records of 35 patients. Int J Oral Maxillofac Surg. 2004;33:761-5.
5. Barker BF, Carpenter WM, Daniels TE, et al. Oral mucosal melanomas: the WESTOP Banff workshop proceedings. Western Society of Teachers of Oral Pathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;83:672-9.
6. Umeda M, Komatsubara H, Shigeta T, et al. Treatment and prognosis of malignant melanoma of the oral cavity: preoperative surgical procedure increases risk of distant metastasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:51-7.
7. Mücke T, Hölzle F, Kesting MR, et al. Tumor size and depth in primary malignant melanoma in the oral cavity influences survival. J Oral Maxillofac Surg. 2009;67:1409-15.
8. Lopez-Graniel CM, Ochoa-Carrillo FJ, Meneses-García A. Malignant melanoma of the oral cavity: diagnosis and treatment experience in a Mexican population. Oral Oncol. 1999;35:425-30.
9. Yang X, Ren GX, Zhang CP, et al. Neck dissection and post-operative chemotherapy with dimethyl triazeno imidazole carboxamide and cisplatin protocol are useful for oral mucosal melanoma. BMC Cancer. 2010;10:623.
10. Umeda M, Shimada K. Primary malignant melanoma of the oral cavity - its histological classification and treatment. Br J Oral Maxillofac Surg. 1994;32:39-47.
11. Vikey AK, Vikey D. Primary malignant melanoma, of head and neck: a comprehensive review of literature. Oral Oncol. 2012;48:399-403.
12. Kruse AL, Riener MO, Graetz KW, et al. Mucosal malignant melanomas in head and neck surgery: a retrospective study of six patients and review of the literature. Oral Maxillofac Surg. 2010;14:143-7.
13. Liu YS, Zhang WD, Yang CH, et al. Effect of interferon alfa therapy on malignant melanoma of oral mucosa. Shanghai Kou Qiang Yi Xue. 2006;15:263-8.
14. Kraal JH, Hussain AA, Gregorio SB, et al. Exposure time and the effect of hexylresorcinol on bacterial aggregates. J Dent Res. 1979;58:2125-31.
15. National Toxicology Program. NTP toxicology and carcinogenesis studies of 4-hexylresorcinol (CAS No. 136-77-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies). Toxicol Program Tech Rep Ser. 1988;330:1-166.
16. Kim SG, Jeong JH, Park YW, et al. 4-Hexylresorcinol inhibits transglutaminase-2 activity and has synergistic effects along with cisplatin in KB cells. Oncol Rep. 2011;25:1597-602.
17. Kim SG, Lee SW, Park YW, et al. 4-hexylresorcinol inhibits NF-κB phosphorylation and has a synergistic effect with cisplatin in KB cells. Oncol Rep. 2011;26:1527-32.
18. Arias E, González J, Peiró JM, et al. Browning prevention by ascorbic acid and 4-hexylresorcinol: different mechanisms of action on polyphenol oxidase in the presence and in the absence of substrates. J Food Sci. 2007;72:C464-70.
19. Thepnuan R, Benjakul S, Visessanguan W. Effect of pyrophosphate and 4-hexylresorcinol pretreatment on quality of refrigerated white shrimp (Litopenaeus vannamei) kept under modified atmosphere packaging. J Food Sci. 2008;73:S124-33.
20. Shattuck-Brandt RL, Richmond A. Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Cancer Res. 1997;57:3032-9.
21. Kim SG, Kim MH, Chae CH, et al. Downregulation of matrix metalloproteinases in hyperplastic dental follicles results in abnormal tooth eruption. BMB Rep. 2008;41:322-7.
22. Park YW, Kim SG, Choi JY, et al. Recapitulating orthotopic tumor model through establishment of a parotid gland tumor with lung metastasis using HeLa cell injection into nude mice. Oncol Rep. 2010;23:701-8.
23. Carlsson G, Gullberg B, Hafström L. Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol. 1983;105:20-3.
24. Johnson AJ, Lucas DM, Muthusamy N, et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood. 2006;108:1334-8.
25. Kim SG, Hahn BD, Park DS, et al. Aerosol deposition of hydroxyapatite and 4-hexylresorcinol coatings on titanium alloys for dental implants. J Oral Maxillofac Surg. 2011;69:e354-63.
26. Lourenço SV, Sangueza MS, Sotto MN, et al. Primary oral mucosal melanoma: a series of 35 new cases from South America. Am J Dermatopathol. 2009;31:323-30.
27. Patel SG, Prasad ML, Escrig M, et al. Primary mucosal malignant melanoma of the head and neck. Head Neck. 2002;24:247-57.
28. Nayak MT, Singh A, Mathur RM, et al. Second primary oral melanoma: a rare presentation. J Oral Maxillofac Pathol. 2012;16:88-90.
29. Calabrese V, Cifola M, Pareschi M, et al. Primary malignant melanomas of the oral cavity. J Laryngol Otol. 1989;103:887-9.
30. Tucci R, Aburad De Carvalhosa A, Anunciação G, et al. Late diagnosis of a primary oral malignant melanoma: a case report. Minerva Stomatol. 2010;59:55-9.
31. Chen QX, Ke LN, Song KK, et al. Inhibitory effects of hexylresorcinol and dodecylresorcinol on mushroom (Agaricus bisporus) tyrosinase. Protein J. 2004;23:135-41.
32. Lin YS, Chuang MT, Chen CH, et al. Nicotinic acid hydroxamate downregulated the melanin synthesis and tyrosinase activity through activating the MEK/ERK and AKT/GSK3β signaling pathways. J Agric Food Chem. 2012;60:4859-64.
33. McLean N, Tighiouart M, Muller S. Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma. Oral Oncol. 2008;44:1039-46.
34. Meleti M, Leemans CR, de Bree R, et al. Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy. Head Neck. 2008;30:1543-51.
35. Chiarion-Sileni V, Guida M, Ridolfi L, et al. Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine-based regimens. Br J Cancer. 2011;104:1816-21.
36. Lens MB, Eisen TG. Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother. 2003;4:2205-11.
37. Jordan VC. Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol. 1993;110:507-17.
38. Beguerie JR, Xingzhong J, Valdez RP. Tamoxifen vs. non-tamoxifen treatment for advanced melanoma: a meta-analysis. Int J Dermatol. 2010;49:1194-202.
39. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008;26:2046-51.
40. Wennerberg J, Biörklund A, Tropé C. The effect of cisplatin and fluorouracil on xenografted human squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1988;114:162-7.
41. Johnsson A, Olsson C, Nygren O, et al. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol. 1995;37:23-31.
42. Tanaka T, Nakayama H, Yoshitake Y, et al. Selective inhibition of nuclear factor-κB by nuclear factor-κB essential modulator-binding domain peptide suppresses the metastasis of highly metastatic oral squamous cell carcinoma. Cancer Sci. 2012;103:455-63.
43. Zhou CX, Gao Y, Johnson NW, et al. Immunoexpression of matrix metalloproteinase-2 and matrix metalloproteinase-9 in the metastasis of squamous cell carcinoma of the human tongue. Aust Dent J. 2010;55:385-9.
44. Daniele A, Zito AF, Giannelli G, et al. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Res. 2010;30:3521-7.
45. Hojo K, Maki H, Sawada TY, et al. Augmented growth inhibition of B16-BL6 melanoma by combined treatment with a selective matrix metalloproteinase inhibitor, MMI-166, and cytotoxic agents. Anticancer Res. 2002;22:3253-9.